TABLE 2.
Summary of hydrogen bonds formed between sifalimumab Fab and IFN-α2A
| Sifalimumab | Distance (Å) | IFN-α2A |
|---|---|---|
| CDRH1 | ||
| Ser-31 (O)a,b | 3.0 | Gln-90 (Oϵ1) |
| Tyr-32 (Oη) | 3.0 | Thr-86 (O)b |
| Ser-33 (Oγ) | 2.9 | Asn-93 (Nδ2) |
| Ser-33 (N)b | 3.1 | Asn-93 (Nδ2) |
| CDRL1 | ||
| Ser-30 (Oγ) | 3.2 | Thr-106 (Oγ) |
| Ser-30 (Oγ) | 2.8 | Met-111 (O)b |
| Ser-31 (N)b | 2.9 | Glu-113 (Oϵ1) |
| Ser-31 (Oγ) | 2.4 | Glu-113 (Oϵ2) |
| Ser-31 (Oγ) | 3.1 | Arg-120 (Nη2) |
| Thr-32 (Oγ1) | 3.0 | Gln-61 (Nϵ2) |
| Thr-32 (O)b | 2.6 | His-57 (Nδ1) |
| Thr-32 (O)b | 2.9 | Glu-58 (Oϵ1) |
| Thr-32 (O)b | 2.9 | Gln-61 (Νϵ2) |
| CDRH2 | ||
| Asn-55 (Nδ2) | 3.6 | Asp-2 (Oδ2) |
| FRL2c | ||
| Tyr-50 (Oη) | 3.3 | Gln-61 (O)b |
| Tyr-50 (Oη) | 3.4 | Asn-65 (Nδ2) |
| CDRL2 | ||
| Gly-51 (O)b | 3.0 | Arg-120 (Nη2) |
| Arg-55 (O)b | 3.7 | Asn-65 (δ2) |
| CDRH3 | ||
| Ile-101 (N)b | 3.4 | Glu-96 (ϵ1) |
| Ile-101 (N)b | 3.6 | Glu-96 (Oϵ2) |
| CDRL3 | ||
| Tyr-92 (Oη) | 2.8 | Gln-61 (Nϵ2) |
| Arg-97 (Nη2) | 3.7 | Glu-96 (Oϵ1) |
a Letters in parentheses refer to the corresponding interacting atoms.
b Main chain atoms.
c FR, framework.